Floatz logo

su011248

Recurrent Thyroid Gland Carcinoma

University Medical Center GroningenPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Recurrent Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 2CCC
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC

View all 37 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →